Cabergoline

• 产品号: C0246
• CAS号: 81409-90-7
• 分子式: C26H37N5O2
• 分子量: 451.60428
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: Cabergoline
• IUPAC标准名: 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^2,^7.0^1^2,^1^6]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
• IUPAC传统名: cabergoline
• 别名: Dostinex; 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea; Cabaser; 1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea; FCE-21336

产品登记号

• MDL号: MFCD00867887
• CAS号: 81409-90-7

产品性质

• Empirical Formula (Hill Notation): C26H37N5O2
• 纯度: ≥98% (HPLC)
• 外观: powder
• 溶解度: DMSO: ≥10 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302-H315-H319-H335
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• GHS警示性声明: P261-P305 + P351 + P338
• 危险公开号: 36/37/38
• RTECS编号: KE6167600
• 安全公开号: 26-36/37
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

详细说明 (简体中文)

Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).